Merck Gross Profit 2010-2022 | MRK

Merck annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Merck gross profit for the quarter ending June 30, 2022 was $10.377B, a 25.05% increase year-over-year.
  • Merck gross profit for the twelve months ending June 30, 2022 was $40.250B, a 42.35% increase year-over-year.
  • Merck annual gross profit for 2021 was $35.078B, a 25.73% increase from 2020.
  • Merck annual gross profit for 2020 was $27.9B, a 2.93% increase from 2019.
  • Merck annual gross profit for 2019 was $27.105B, a 5.84% decline from 2018.
Merck Annual Gross Profit
(Millions of US $)
2021 $35,078
2020 $27,900
2019 $27,105
2018 $28,785
2017 $27,210
2016 $25,777
2015 $24,564
2014 $25,469
2013 $27,079
2012 $30,821
2011 $31,176
2010 $27,591
2009 $18,409
Merck Quarterly Gross Profit
(Millions of US $)
2022-06-30 $10,377
2022-03-31 $10,521
2021-12-31 $9,648
2021-09-30 $9,704
2021-06-30 $8,298
2021-03-31 $7,428
2020-12-31 $4,633
2020-09-30 $7,916
2020-06-30 $6,606
2020-03-31 $8,745
2019-12-31 $2,575
2019-09-30 $8,407
2019-06-30 $8,359
2019-03-31 $7,764
2018-12-31 $7,709
2018-09-30 $7,175
2018-06-30 $7,048
2018-03-31 $6,853
2017-12-31 $6,993
2017-09-30 $7,018
2017-06-30 $6,814
2017-03-31 $6,385
2016-12-31 $6,644
2016-09-30 $7,127
2016-06-30 $6,266
2016-03-31 $5,740
2015-12-31 $6,365
2015-09-30 $6,312
2015-06-30 $6,031
2015-03-31 $5,856
2014-12-31 $6,733
2014-09-30 $6,334
2014-06-30 $6,041
2014-03-31 $6,361
2013-12-31 $6,713
2013-09-30 $6,928
2013-06-30 $6,726
2013-03-31 $6,712
2012-12-31 $7,577
2012-09-30 $7,351
2012-06-30 $8,199
2012-03-31 $7,694
2011-12-31 $8,118
2011-09-30 $7,670
2011-06-30 $7,867
2011-03-31 $7,521
2010-12-31 $7,654
2010-09-30 $6,934
2010-06-30 $6,797
2010-03-31 $6,206
2009-12-31 $5,192
2009-09-30 $4,619
2009-06-30 $4,546
2009-03-31 $4,051
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.457B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $433.657B 16.51
Eli Lilly (LLY) United States $295.599B 37.48
AbbVie (ABBV) United States $250.575B 10.65
Pfizer (PFE) United States $247.449B 7.25
Novo Nordisk (NVO) Denmark $217.019B 28.63
Novartis AG (NVS) Switzerland $165.171B 12.18